|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||20.38 - 20.53|
|52 Week Range||17.64 - 22.27|
|PE Ratio (TTM)||63.34|
|Forward Dividend & Yield||0.24 (1.18%)|
|1y Target Est||N/A|
athenahealth (ATHN) witnessed a year-over-year increase in Q3 revenues on the back of strength in its Business and Services segment.
Rapidly changing healthcare environment in the United States, unfavorable price movement, a competitive dental products distribution industry and integration risks pose significant challenges for Patterson Companies (PDCO).
Intensifying competition, foreign exchange volatility, higher raw material costs and integration risks are primary headwinds for Ecolab (ECL) as of now.
In August, management at Ecolab (ECL) announced that equipment care business has been witnessing a quiet period, registering just 2% growth on a year-over-year basis in the last quarter.
The cost-effectiveness of cloud-based applications over in-premise applications is attracting life science companies. Veeva's (VEEV) industry-specific focus lends it a significant leverage.
Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.
DaVita HealthCare Partners' (DVA) focus on acquisitions will boost the company's expansion. However, rising expenses remains headwind.
NeoTract acquisition is expected to generate mid-single digit constant currency revenue growth for the next several years and enhance Teleflex's (TFX) margins.
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.
Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.
Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.
Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.
Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.
Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.
AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.
Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Luminex Corp. a score of 72. Our analysis is based on comparing Luminex Corp. with the following peers – Illumina, Inc., Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc. Class A, Abbott Laboratories, Hologic, Inc., Pacific Biosciences of California, Inc., NanoString Technologies, Inc. and ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Luminex Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Alcoa, Cheesecake Factory, Luminex, Ligand Pharmaceuticals and Centene highlighted as Zacks Bull and Bear of the Day